Despite the well-established roles of interferon (IFN) pathways in priming of antiviral immunity and evidence that pre-existing defects of type I IFN responses are associated with adverse prognosis12,13, recombinant type I IFN therapy failed to improve COVID-19 outcomes14 and may even be detrimental in severe disease15. This evidence concerns the gene IFNA1 and COVID-19.